ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物医药技术（上海）股份有限公司

01541.HK

Clinical-stage biotechnology company in the PRC developing immuno-oncology therapies, with a pipeline of 14 drug candidates centered on CD47-targeted innate-immunity assets, including CD47-based bispecific molecules, for cancer treatment.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Business changes and acquisitions
• Capacity and utilisation
• Losses and path to profitability
• Decline in revenue or profit
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Non-recurring gains and losses
• Related-party transactions and balances
• Material share-based payments
• Chapter 18A biotech